https://scholars.lib.ntu.edu.tw/handle/123456789/543442
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Satoh T. | en_US |
dc.contributor.author | Kang Y.-K. | en_US |
dc.contributor.author | Chao Y. | en_US |
dc.contributor.author | Ryu M.-H. | en_US |
dc.contributor.author | Kato K. | en_US |
dc.contributor.author | Cheol Chung H. | en_US |
dc.contributor.author | Chen J.-S. | en_US |
dc.contributor.author | Muro K. | en_US |
dc.contributor.author | Ki Kang W. | en_US |
dc.contributor.author | KUN-HUEI YEH | en_US |
dc.contributor.author | Yoshikawa T. | en_US |
dc.contributor.author | Oh S.C. | en_US |
dc.contributor.author | Bai L.-Y. | en_US |
dc.contributor.author | Tamura T. | en_US |
dc.contributor.author | Lee K.-W. | en_US |
dc.contributor.author | Hamamoto Y. | en_US |
dc.contributor.author | Kim J.G. | en_US |
dc.contributor.author | Chin K. | en_US |
dc.contributor.author | Oh D.-Y. | en_US |
dc.contributor.author | Minashi K. | en_US |
dc.contributor.author | Cho J.Y. | en_US |
dc.contributor.author | Tsuda M. | en_US |
dc.contributor.author | Tanimoto M. | en_US |
dc.contributor.author | Chen L.-T. | en_US |
dc.contributor.author | Boku N. | en_US |
dc.creator | Satoh T.;Kang Y.-K.;Chao Y.;Ryu M.-H.;Kato K.;Cheol Chung H.;Chen J.-S.;Muro K.;Ki Kang W.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Tanimoto M.;Chen L.-T.;Boku N. | - |
dc.date.accessioned | 2021-01-28T01:06:17Z | - |
dc.date.available | 2021-01-28T01:06:17Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065787461&doi=10.1007%2fs10120-019-00970-8&partnerID=40&md5=065b859af3291472b98f4b30d25753d5 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/543442 | - |
dc.description.abstract | Background: Data on immune checkpoint inhibitor efficacy in patients with human epidermal growth factor receptor 2-positive (HER2+) advanced gastric/gastroesophageal junction (G/GEJ) cancer are lacking. Because HER2 status was not captured in the ATTRACTION-2 trial, we used patients with prior trastuzumab use (Tmab+) as surrogate for HER2 expression status to evaluate the efficacy and safety of nivolumab as third- or later-line therapy in these patients. Methods: In ATTRACTION-2, a randomized, double-blind, placebo-controlled, phase 3 multicenter trial, patients were randomized (2:1) to receive nivolumab (3?mg/kg) or placebo every 2?weeks until disease progression or toxicity requiring study discontinuation. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety were assessed. Results: Of 493 enrolled patients, 81 (nivolumab, n = 59; placebo, n = 22) were Tmab+ and 412 (nivolumab, n = 271; placebo, n = 141) were Tmab?. In both groups, patients receiving nivolumab showed a longer median OS vs placebo (Tmab+, 8.3 [95% confidence interval, 5.3–12.9] vs 3.1 [1.9–5.3] months, hazard ratio, 0.38 [0.22–0.66]; P = 0.0006; Tmab?, 4.8 [4.1–6.0] vs 4.2 [3.6–4.9] months, 0.71 [0.57–0.88]; P = 0.0022). PFS was longer in both groups receiving nivolumab vs placebo (Tmab+, 1.6 [1.5–4.0] vs 1.5 [1.3–2.9] months, 0.49 [0.29–0.85]; P = 0.0111; Tmab?, 1.6 [1.5–2.4] vs 1.5 [1.5–1.5]?months, 0.64 [0.51–0.80]; P = 0.0001). Conclusions: Nivolumab was efficacious and safe as third- or later-line therapy regardless of prior trastuzumab use in patients with advanced G/GEJ cancer. ? 2019, The Author(s). | - |
dc.publisher | Springer | - |
dc.relation.ispartof | Gastric Cancer | - |
dc.subject | Gastric cancer; Gastroesophageal junction?cancer; Nivolumab; Trastuzumab | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | immunological antineoplastic agent; nivolumab; placebo; trastuzumab; adult; aged; clinical trial; controlled study; double blind procedure; esophagus tumor; female; gastroesophageal junction; human; male; middle aged; mortality; pathology; phase 3 clinical trial; randomized controlled trial; stomach tumor; treatment outcome; very elderly; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Nivolumab; Placebos; Stomach Neoplasms; Trastuzumab; Treatment Outcome | - |
dc.title | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1007/s10120-019-00970-8 | - |
dc.identifier.pmid | 31087200 | - |
dc.identifier.scopus | 2-s2.0-85065787461 | - |
dc.relation.pages | 143-153 | - |
dc.relation.journalvolume | 23 | - |
dc.relation.journalissue | 1 | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.orcid | 0000-0002-7306-174X | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。